21 May 2013
Keywords: crucell, manufacture, parts, wyeth, vaccine, dutch, biotechnology
Article | 10 March 2008
Dutch biotechnology company Crucell NV has entered into an exclusive vaccine development agreement with US drug major Wyeth. Under the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 March 2008
20 May 2013
© 2013 thepharmaletter.com